5:35 PM
 | 
Oct 30, 2012
 |  BC Extra  |  Clinical News

Masitinib misses Phase III OS endpoint in pancreatic cancer

AB Science S.A. (Euronext:AB) reported late Tuesday that masitinib plus Gemzar gemcitabine missed the primary endpoint of median overall survival (OS) vs. placebo plus Gemzar in a Phase III trial to treat pancreatic cancer (7.7 vs. 7 months, p=0.74). In a subgroup of patients with an undisclosed genetic biomarker that the company said is indicative of...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >